ReviewFrontiers in pharmacology2016
Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed.
- Porosity-engineered long-acting protopanaxadiol microspheres prevent CDK4/6 inhibitor-induced myelosuppression.Materials today. Bio · 2026Article
- Microfluidic Production of Dexamethasone-Loaded PLGA Microparticles: Dynamic Solvent Extraction Improves Process Robustness During the Droplet-to-Particle Transition.Pharmaceutics · 2026Article
- "Biodegradable caterpillar inspired soft robotic systems for targeted therapeutic delivery with intelligentRSC advances · 2026Review
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Comparing the efficacy of nanocarriers for cutaneous and follicular delivery of poorly water-soluble molecules: A case study with ciclosporin A.International journal of pharmaceutics: X · 2026Article
- Electrosprayed PLGA Nanoparticles for Dual Drug Delivery: Design, Optimization and Applications.Polymers · 2026Review
- Polymeric anti-platelet carriers for the precision-targeting of age-related cardiovascular and cerebrovascular diseases.Materials today. Bio · 2026Review
- Targeted 2-Deoxy-D-Ribose Delivery by Biomimetic Nanoplatform Activates EGFR for Accelerated Heart Valve Endothelialization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanoparticle-Based Oral Insulin Delivery: Challenges, Advances, and Future Directions.Pharmaceutics · 2025Review
- Extended osteoarthritis pain relief with neosaxitoxin using alginate-core polymeric microparticles.Nanoscale · 2025Article
- Encapsulation of Therapeutic, Low-Molecular-Weight Chemokines Using a Single Emulsion, Microfluidic, Continuous Manufacturing Process.Pharmaceutics · 2025Article
- Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery.Molecular pharmaceutics · 2025Review
- Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual-Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Development of Itaconate Polymers Microparticles for Intracellular Regulation of Pro-Inflammatory Macrophage Activation.Advanced healthcare materials · 2025Article
- Colon-Targeted Mucoadhesive PLGA Microspheres Loaded withMolecules (Basel, Switzerland) · 2025Article
- Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug delivery and translational research · 2025Review
- Taylor dispersion analysis and release studies of β-carotene-loaded PLGA nanoparticles and liposomes in simulated gastrointestinal fluids.RSC advances · 2025Article
- Investigation of the Thermal Stability and Hydrolytic Degradation Kinetics of Poly(Lactide-co-Glycolide) Melts.AAPS PharmSciTech · 2025Article
- The neurobiology of plant-based therapeutics in women's reproductive health: mechanisms, efficacy, and clinical translation.Frontiers in nutrition · 2025Review
- The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers.Heliyon · 2024Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly(lactic-co-glycolic acid) (PLGA) is the most widely used biomaterial for microencapsulation and prolonged delivery of therapeutic drugs, proteins and antigens. PLGA has excellent biodegradability and biocompatibility and is generally recognized as safe by international regulatory agencies including the United States Food and Drug Administration and the European Medicines Agency. The physicochemical properties of PLGA may be varied systematically by changing the ratio of lactic acid to glycolic acid. This in turn alters the release rate of microencapsulated therapeutic molecules from PLGA microparticle formulations. The obstacles hindering more widespread use of PLGA for producing sustained-release formulations for clinical use include low drug loading, particularly of hydrophilic small molecules, high initial burst release and/or poor formulation stability. In this review, we address strategies aimed at overcoming these challenges. These include use of low-temperature double-emulsion methods to increase drug-loading by producing PLGA particles with a small volume for the inner water phase and a suitable pH of the external phase. Newer strategies for producing PLGA particles with high drug loading and the desired sustained-release profiles include fabrication of multi-layered microparticles, nanoparticles-in-microparticles, use of hydrogel templates, as well as coaxial electrospray, microfluidics, and supercritical carbon dioxide methods. Another recent strategy with promise for producing particles with well-controlled and reproducible sustained-release profiles involves complexation of PLGA with additives such as polyethylene glycol, poly(ortho esters), chitosan, alginate, caffeic acid, hyaluronic acid, and silicon dioxide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.